MBX Biosciences' Investigational Drug For Weight Loss Surgery-Related Low Blood Sugar Shows Encouraging Action
MBX Biosciences Inc. (NASDAQ:MBX) revealed results from its Phase 1 single ascending dose and multiple ascending dose trial ...
MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia
Phase 1 results support proceeding to Phase 2 in patients with post-bariatric hypoglycemia (PBH),which is expected to begin in 2H 2025Phase 1 ...
GlobalData on MSN10h
Metsera announces positive results in newest Phase IIa GLP-1RA
The New York company is hoping to enter the GLP-1RA space with its newest offering requiring dosing every month over ...
Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study
New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight ...
MBX Biosciences, Inc.: MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia
Phase 1 results support proceeding to Phase 2 in patients with post-bariatric hypoglycemia (PBH), which is expected to begin in 2H 2025 Phase 1 trial in healthy volunteers showed MBX 1416 was generall ...
ecoportal.net7h
The first American state to cover Ozempic — Only federal health insurance needed
Discover how North Dakota is leading the way by covering Ozempic for weight loss under ACA plans, making it the first U.S.
Weed war of Capitol proportions
BEHIND CLOSED DOORS: A four-hour House Democratic Caucus meeting in Springfield was so contentious that a member of Gov. JB Pritzker ’s team left in tears and the hemp legislation that was at the ...
Healio9h
GLP-1 receptor agonists may improve outcomes for patients with morbid obesity after TKA
Results showed patients with a BMI of 40 kg/m2 or more who used glucagon-like peptide-1 receptor agonists for at least 90 ...